Jubilant Pharmova Ltd
Jubilant Pharmova Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #65 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward. Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA. - Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state. - Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve. - Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan. - Lean 2.0 cost optimization program targeting Rs.
From Jubilant Pharmova Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward.
- Overall business is projected to grow at 20%-25% year-on-year driven by specialty and export growth.
- CDMO business pipeline is strong, with 70+ active opportunities; pharma funnel has doubled in one year.
- Agro CDMO contracts progressing; more contracts expected in coming months.
- Semiconductor segment has 12+ opportunities, with near commercial stage molecules.
- New multipurpose plants and capacity debottlenecking underway to support growth.
- Niacinamide plant commissioning to accelerate growth in human nutrition.
- Big agro CDMO order supplies to start early 2026.
- Recovery expected in Acetyl segment with improving volumes and margins.
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Completed Rs. 2000 crore investment largely into specialty chemicals, including multipurpose and dedicated plants for CDMO and Fine Chemicals.
- Major dedicated plant construction in Bharuch expected to complete by end of FY'26.
- Commissioning of a new boiler at Bharuch scheduled for Q2 FY'26.
- Debottlenecking initiatives to increase capacity by 15%-20% at existing multipurpose plants in Bharuch and Gajraula.
- Detailed engineering started for a new multipurpose plant (MPP8) at Gajraula, with construction expected to begin in the next few months.
- Conversion of recently commissioned niacinamide plant into a multipurpose plant for human nutrition segment underway.
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The CDMO business pipeline has doubled in the last year, with about 70 molecules in the funnel, representing addressable markets running into thousands of crores.
- Orders include a big $300 million agro CDMO contract, with plant construction ongoing and supplies expected to start early 2026.
- Two agro CDMO contracts were awarded last year; five to six more are in advanced stages or discussions.
- Multiple opportunities exist in pharma, agro, and semiconductor segments, with 12+ pipeline opportunities in semiconductor alone.
- The company is actively engaging with 30+ key accounts across geographies (EU, US, Japan) to convert opportunities into orders.
2 more points from Jubilant Pharmova Ltd's call on order book
Create a free account to keep reading this call
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY25 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q1 FY22 earnings call →
- Q4 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q1 FY26 results?
Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward. Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA. - Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state. - Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve. - Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan. - Lean 2.0 cost optimization program targeting Rs.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 33.8 with a market cap of ₹14,730 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Completed Rs.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.